stockrow
Saturday 7 November 2026
Export RDY’s income statement to Excel — free account
Dr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
14.86
0.33
+2.27%
Follow RDY
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
38.58 | 36.49 | 25.79 | 18.23 |
+8 more quarters Free account |
P/S ratio |
3.15 | 3.30 | 3.22 | 2.97 | |
P/FCF ratio |
109.45 | 81.66 | 53.62 | 40.59 | |
P/Operating CF |
187.63 | (1,135.05) | 77.38 | 99.07 | |
P/B ratio |
2.59 | 2.78 | 2.84 | 2.79 | |
Price to Tangible BV |
3.70 | 3.98 | 4.12 | 4.02 | |
EV/Sales |
3.14 | 3.27 | 3.19 | 2.93 | |
EV/EBITDA |
19.86 | 18.87 | 15.04 | 11.71 | |
EV/Operating CF |
33.42 | 26.40 | 18.81 | 16.07 | |
EV/FCF |
108.97 | 80.90 | 53.09 | 40.00 | |
Quick Ratio |
1.15 | 1.16 | 1.13 | 1.18 | |
Current Ratio |
1.93 | 1.90 | 1.80 | 1.88 | |
Net Debt/EBITDA |
(0.25) | (1.07) | (4.36) | (0.78) | |
Debt/Assets |
12.56% | 12.51% | 13.34% | 12.03% | |
Debt/Equity |
0.19 | 0.19 | 0.20 | 0.18 | |
Asset Turnover |
0.55 | 0.57 | 0.60 | 0.66 | |
Operating CF/Net income |
0.58 | (0.21) | (13.83) | 0.87 | |
Capex/Depreciation |
(0.70) | (0.23) | (1.72) | (1.34) | |
Interest Coverage |
10.16 | 2.93 | (2.99) | 15.08 | |
Research and Development Expense of Revenue |
6.04% | 7.15% | 7.22% | 7.05% | |
Selling, General and Administrative Expense of Revenue |
32.38% | 35.64% | 39.21% | 30.85% | |
Intangible Assets out of Total Assets |
0.20 | 0.20 | 0.20 | 0.20 | |
Share Based Compensation of Revenue |
0.11% | 0.12% | 0.00% | 0.10% | |
Graham Net Nets |
0.11 | 0.10 | 0.10 | 0.11 | |
Graham Number |
5.99 | 6.83 | 7.67 | 9.33 | |
Earnings Yield |
2.59% | 2.74% | 3.88% | 5.48% | |
Free Cash Flow Yield |
0.91% | 1.22% | 1.86% | 2.46% | |
Revenue per Share |
1.09 | 1.09 | 0.71 | 1.17 | |
Operating CF per Share |
0.07 | (0.01) | 0.18 | 0.14 | |
Capex per Share |
(0.05) | (0.02) | (0.11) | (0.09) | |
Free Cash Flow per Share |
0.02 | (0.03) | 0.07 | 0.05 | |
Cash per Share |
0.96 | 1.10 | 1.13 | 1.11 | |
Shareholders Equity per Share |
4.88 | 5.22 | 4.87 | 5.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.88 | 5.22 | 4.87 | 5.02 | |
Free Cash Flow |
18.00 | (23.00) | 58.00 | 43.00 | |
Working Capital |
1,493.00 | 1,501.00 | 1,432.00 | 1,550.00 | |
Capital Expenditures |
(38.00) | (13.00) | (91.00) | (75.00) | |
Net Current Asset Value |
1,173.00 | 1,171.00 | 1,098.00 | 1,229.00 | |
EV/EBIT |
34.10 | 29.99 | 21.18 | 15.10 | |
Capex to Sales |
0.04 | 0.02 | 0.15 | 0.08 | |
Price to Operating Income |
34.25 | 30.27 | 21.39 | 15.32 | |
| Other line items | |||||
Average Receivables |
1,079.50 | 1,086.00 | 1,068.50 | 1,113.50 | |
Average Payables |
415.00 | 416.50 | 386.50 | 437.50 | |
Average Inventory |
850.50 | 866.00 | 824.00 | 858.00 | |
Average Assets |
6,050.00 | 6,069.00 | 5,973.50 | 5,944.50 | |
Average Common Equity |
4,070.50 | 4,105.50 | 4,000.50 | 3,971.50 |
Columns are period end dates · fundamentals updated 2 Nov 2026